Track 4D Molecular Therapeutics's other assets ($0) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
The latest other assets for FDMT is $0 as of March 2026. In the prior-year period, the figure was $0. Investors often review this figure alongside 4D Molecular Therapeutics's historical trend and sector peers before judging valuation or financial health.
Over the past year, FDMT's other assets moved from $0 to $0. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in 4D Molecular Therapeutics's operating scale or balance-sheet position.
A other assets figure of $0 for FDMT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.
After noting FDMT's other assets ($0), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack 4D Molecular Therapeutics's other assets against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.